HK1183874A1 - Inhibitor of casein kinase 1 and casein kinase 1 1 1 - Google Patents

Inhibitor of casein kinase 1 and casein kinase 1 1 1

Info

Publication number
HK1183874A1
HK1183874A1 HK13111396.2A HK13111396A HK1183874A1 HK 1183874 A1 HK1183874 A1 HK 1183874A1 HK 13111396 A HK13111396 A HK 13111396A HK 1183874 A1 HK1183874 A1 HK 1183874A1
Authority
HK
Hong Kong
Prior art keywords
casein kinase
inhibitor
casein
kinase
Prior art date
Application number
HK13111396.2A
Other languages
English (en)
Chinese (zh)
Inventor
岡本雅子
高山喜好
Original Assignee
株式會社 健康研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式會社 健康研究所 filed Critical 株式會社 健康研究所
Publication of HK1183874A1 publication Critical patent/HK1183874A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK13111396.2A 2010-08-09 2013-10-10 Inhibitor of casein kinase 1 and casein kinase 1 1 1 HK1183874A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010178549 2010-08-09
PCT/JP2011/068034 WO2012020726A1 (ja) 2010-08-09 2011-08-08 カゼインキナーゼ１δ及びカゼインキナーゼ１ε阻害剤

Publications (1)

Publication Number Publication Date
HK1183874A1 true HK1183874A1 (en) 2014-01-10

Family

ID=45567692

Family Applications (2)

Application Number Title Priority Date Filing Date
HK13111396.2A HK1183874A1 (en) 2010-08-09 2013-10-10 Inhibitor of casein kinase 1 and casein kinase 1 1 1
HK15112726.9A HK1211926A1 (en) 2010-08-09 2015-12-25 The inhibitor of casein kinase 1 delta and casein kinase 1 epsilon 1 1

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15112726.9A HK1211926A1 (en) 2010-08-09 2015-12-25 The inhibitor of casein kinase 1 delta and casein kinase 1 epsilon 1 1

Country Status (11)

Country Link
US (1) US8710231B2 (ko)
EP (1) EP2604606B1 (ko)
JP (1) JP5181156B2 (ko)
KR (1) KR101856266B1 (ko)
CN (2) CN103097380B (ko)
AU (1) AU2011290238B8 (ko)
CA (1) CA2807359C (ko)
HK (2) HK1183874A1 (ko)
IL (1) IL224612A (ko)
RU (1) RU2562833C2 (ko)
WO (1) WO2012020726A1 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807359C (en) * 2010-08-09 2020-07-07 Pharmadesign, Inc. Inhibitor of casein kinase 1.delta. and casein kinase 1.epsilon.
US11401254B2 (en) * 2018-07-05 2022-08-02 Bayer Aktiengesellschaft Substituted thiophenecarboxamides and analogues as antibacterials agents
CA3111848A1 (en) * 2018-09-09 2020-03-12 Qanatpharma Ag Use of casein kinase 1 inhibitors for treating vascular diseases
US20230053307A1 (en) * 2021-07-19 2023-02-16 Buddhist Tzu Chi Medical Foundation Method for preventing or treating skin disorders and conditions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2819508B1 (fr) * 2001-01-12 2005-01-21 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydorthiazoles, leurs procedes de preparation et leur utilisation therapeutiques
FR2796643B1 (fr) * 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
AU2002313633B2 (en) 2001-06-08 2007-03-01 Cytovia, Inc. Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
MY140489A (en) * 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
PE20051089A1 (es) * 2004-01-22 2006-01-25 Novartis Ag Derivados de pirazolo [1,5-a] pirimidin-7-il-amina como inhibidores de quinasa de proteina
JO2629B1 (en) 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
PT1791537E (pt) * 2004-08-19 2010-01-19 Aventis Pharma Inc Derivados de 3-ariltioindole-2-carboxamida e seus análogos como inibidores da cinase da caseína i
US7531539B2 (en) * 2006-08-09 2009-05-12 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
FR2918986B1 (fr) 2007-07-19 2009-09-04 Sanofi Aventis Sa Derives de 6-cycloamino-3-(pyridazin-4-yl)imidazo[1,2-b]- pyridazine, leur preparation et leur application en therapeutique
JP2009245477A (ja) 2008-03-28 2009-10-22 Hoya Corp 垂直磁気記録媒体
EP2397481B1 (en) * 2009-02-12 2014-03-12 Pharmadesign, Inc. Inhibitor of casein kinase 1delta and casein kinase 1epsilon
CA2807359C (en) * 2010-08-09 2020-07-07 Pharmadesign, Inc. Inhibitor of casein kinase 1.delta. and casein kinase 1.epsilon.

Also Published As

Publication number Publication date
WO2012020726A1 (ja) 2012-02-16
CA2807359C (en) 2020-07-07
US20130137730A1 (en) 2013-05-30
JP5181156B2 (ja) 2013-04-10
EP2604606B1 (en) 2014-10-08
KR101856266B1 (ko) 2018-05-09
RU2562833C2 (ru) 2015-09-10
KR20140000666A (ko) 2014-01-03
EP2604606A1 (en) 2013-06-19
CN103097380A (zh) 2013-05-08
CN104803997A (zh) 2015-07-29
AU2011290238B8 (en) 2015-09-03
HK1211926A1 (en) 2016-06-03
AU2011290238B2 (en) 2014-07-17
AU2011290238A1 (en) 2013-03-21
RU2013107659A (ru) 2014-09-20
US8710231B2 (en) 2014-04-29
CA2807359A1 (en) 2012-02-16
EP2604606A4 (en) 2013-08-07
JPWO2012020726A1 (ja) 2013-10-28
IL224612A (en) 2016-05-31
CN103097380B (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
HK1257444A1 (zh) Cdc7激酶抑制劑以及其用途
HRP20180953T1 (hr) Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe
HK1202333A1 (en) Combination of kinase inhibitors and uses thereof
EP2619184A4 (en) DEUBIQUITINASE INHIBITORS AND METHOD FOR THEIR USE
ZA201300705B (en) Inhibitors of bruton's tyrosine kinase
HK1189587A1 (en) Bromodomain inhibitors and uses thereof
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
EP2696683A4 (en) COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER
HK1160119A1 (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
AP2013006984A0 (en) BicycloÄ3.2.1Üoctyl amide derivatives and uses of same
EP2387572A4 (en) PROTEIN KINASE C HEMMER AND ITS USE
ZA201104146B (en) Dispersions comprising inhibitors of the hydroxyphenylpyruvate-dioxygenase
IL225605A0 (en) Polo-like kinase inhibitors
ZA201206456B (en) Uses of dgati inhibitors
EP2563358A4 (en) INHIBITORS OF PHOSPHOINOSITIDE-DEPENDENT KINASE 1 (PDK1)
EP2384118A4 (en) SPHINGOGUANIDINE AND ITS USE AS AN INHIBITOR OF SPHINGOSINKINASE
EP3581563C0 (en) SHIP INHIBITORS AND THEIR USES
HK1211926A1 (en) The inhibitor of casein kinase 1 delta and casein kinase 1 epsilon 1 1
EP2397481A4 (en) INHIBITOR OF CASEINKINASE 1DELTA AND CASEIN KINASE 1EPSILONE
ZA201300012B (en) Synthesis and use of kinase inhibitors
GB201020357D0 (en) Compounds and methods of making the same
GB201021161D0 (en) Casein kinase 1delta (CK1Delta) inhibitors
GB0805693D0 (en) Combinations of P13-delta and P13-gamma kinase inhibitor compounds